Relieving suffering and restoring quality of life with next generation orthobiologics.
Feed the Fusion
LDGraft is a next-generation rhBMP-2 product currently in a clinical trial for lumbar interbody fusion procedures.
LDGraft also has an FDA Breakthrough Device designation for the Anterior Lumbar Interbody Fusion (ALIF) indication at one level from L3-S1 for patients with degenerative disc disease.
Who we are
LOCATE BIO is an innovative UK MedTech company with industry-leading drug delivery and tissue scaffold capabilities.
Developing next-generation solutions that address unmet musculoskeletal needs
Unleashing and realising potential within a fearless organisation
Develop next-generation products capable of dominating each of their market segments
Meet the Team
A dedicated team of industry-leading experts.